Amendments to the Claims

Please cancel claims 50, 71-72, 77-88 and 90 without prejudice or disclaimer.

The listing of claim will replace all prior versions and listings of claims in the application:

Listing of claims:

Claims 1–48. Canceled

Claim 49. (currently amended) An isolated nucleic acid molecule encoding a fusion polypeptide, wherein the fusion polypeptide consists of a first subunit comprising ~~at least one copy of the~~ a receptor binding domain of angiopoietin-1, ~~the first subunit being~~ fused to ~~the~~ an N-terminal end of a multimerizing component, and the multimerizing component ~~being~~ fused at its C-terminal end to a second ~~subunit comprising at least one copy of the~~ receptor binding domain of angiopoietin-1, wherein the multimerizing component is an immunoglobulin derived domain selected from the group consisting of the Fc domain of IgG and the heavy chain of IgG.

Claims 50-58. (Canceled)

Claim 59. (currently amended) A fusion polypeptide encoded by the isolated nucleic acid molecule of claim 49 ~~or 50~~.

Claim 60. (previously presented) The fusion polypeptide of claim 59, wherein the fusion polypeptide is multimerized.

Claim 61. (Previously presented) A composition comprising the multimerized fusion polypeptide of claim 60.

Claim 62. (previously amended) The composition of claim 61, wherein the multimer is a dimer formed by interaction between the multimerizing components of two adjacent fusion polypeptide molecules.

Claim 63. (currently amended) A vector which comprises the isolated nucleic acid molecule of claim 49 ~~or 50~~.

Claim 64. (currently amended) An expression vector comprising an isolated nucleic acid molecule of claim 49 ~~or 50~~, wherein the nucleic acid molecule is operatively linked to an expression control sequence.

Claim 65. (Previously presented) A host-vector system for the production of a fusion polypeptide which comprises the expression vector of claim 64, in a suitable host cell.

Claim 66. (Previously presented) The host-vector system of claim 65, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell or mammalian cell.

Claim 67. (Previously presented) The host-vector system of claim 66, wherein the suitable host cell is *E. coli.*

Claim 68. (Previously presented) The host-vector system of claim 66, wherein the suitable host cell is a COS cell.

Claim 69. (Previously presented) The host-vector system of claim 66, wherein the suitable host cell is a CHO cell.

Claim 70. (Previously presented) A method of producing a fusion polypeptide which comprises growing cells of the host-vector system of claim 66, under conditions permitting production of the fusion polypeptide and recovering the polypeptide so produced.

Claims 71-88. Canceled.

Claim 89. (currently amended) The composition of claim 61 wherein the multimer is tetrameric with respect to Ang1-fibrinogen domain (FD).

Claim 90. (canceled)

Claim 91. (new) The nucleic acid molecule of claim 49, comprising SEQ ID NO:5.